CellaVision AB (publ) (CEVI) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

thank you very much and thank you for to everybody for dialing in to the first quarterly reporting here in 2025 i have our cfo magnus blix with me and we are pleased to present the q1 results of the television So the heading of the quarter of our report is strong quarter in a rapidly changing environment. We are reporting a revenue of 195 million, so it represents a growth somewhat above 14% and 14.1% organically. So we believe and we are reporting a pretty strong start to the year. And that is really a contribution from the three regions, but also given the attractions of our solutions across many markets. We know that the nature of our business is really subject to some quarterly fluctuations, given our order-based sales processes, as you may know, the ones who have followed the firm for four years, but also the delivery timing of entire bloodlines is a function here. However, we are proud to get a good head start to the new financial year and I'm pleased to elaborate a little bit more on that and then we will do the Q&A. Essentially, with this result, it also emphasizes and it contributes to our strong financial position. We have very, very little debt on the balance sheet and now a very strong, still a strong cash position that is growing, including a pretty strong operational cash flow. In terms of the progress on our strategic direction, we have chosen to highlight some of the themes that we are investing in. We have increasingly invested in R&D as part of our power of focus. And we're in the midst of a very rich and valuable roadmap. So we are continuing our clinical trials for the application of a bone marrow module that will allow us to classify the different cell intermediates of bone marrow. So that's continuing, you know, according to plan. We're also tod...